参考文献/References:
[1] Zhu G, Xie L, Miller D. Expression of microRNAs in thyroid carcinoma[J].Methods Mol Biol,2017,1617:261-280.DOI:10.1007/978-1-4939-7046-9_19.
[2] Chrus'cik A, Lam AK. Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: a crucial review[J].Exp Mol Pathol,2015,99(3):393-398. DOI:10.1016/j.yexmp.2015.08.013.
[3] Deng X,Wu B,Xiao K,et al. MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3[J].Cell Physiol Biochem,2015,35(1):71-82.DOI:10.1159/000369676.
[4] Hu J,Li C,Liu C,et al.Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC[J].Cancer Biomark,2017,18(1):87-94.DOI:10.3233/CBM-161723.
[5] 姜兴莲,张徽,陈晏林,等. MicroRNA-221及白细胞介素-17在甲状腺乳头状癌中的表达及相关性[J].中华病理学杂志,2017,46(3):160-165.DOI:10.3760/cma.j.issn.0529-5807.2017.03.004.
[6] Zhou YL,Liu C,Dai XX,et al. Overexpression of miR-221 is associated with aggressive clinicopathologic characteristics and the BRAF mutation in papillary thyroid carcinomas[J].Med Oncol,2012,29(5):3360-3366.DOI:10.1007/s12032-012-0315-8.
[7] 李元梅,孙利敏,王媛媛,等. microRNA-106b在甲状腺癌中表达的临床意义及生物学功能[J].中华内分泌外科杂志,2017,11(1):60-64.DOI:10.3760/cma.j.issn.1674-6090.2017.01.014.
[8] 贺新伟,林道浙,薛迪新,等. miR-145在甲状腺乳头状癌中的表达及功能研究[J].中华内分泌外科杂志, 2017,11(3): 224-248. DOI:10.3760/cma.j.issn.1674-6090.2017.03.012.
[9] Gu Y,Li D,Luo Q,et al. MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by targeting DUSP6[J].Int J Clin Exp Med,2015,8(6):8590-8598.
[10] 饶丽华,余发斌,潘雪凯,等. Let-7微小RNA在甲状腺乳头状腺癌的表达及其临床意义[J].中华实验外科杂志,2016,33(8):2019-2021. DOI:10.3760/cma.j.issn.1001-9030.2016.08.043.
[11] 谢珲,张欢欢,应华忠,等.微RNA-22在甲状腺乳头状癌中的表达及与化学治疗敏感性的关系[J].国际流行病学传染病学杂志,2017,44(2):95-99.DOI:10.3760/cma.j.issn.1673-4149.2017.02.005.
[12] Haugen BR,Alexander EK,Bible KC,et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133.DOI:10.1089/thy.2015.0020.
[13] Wojtas B,Ferraz C,Stokowy T,et al. Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas[J].Mol Cell Endocrinol,2014,388(1-2):1-9.DOI:10.1016/j.mce.2014.02.011.
[14] Colamaio M,Puca F,Ragozzino E,et al. miR-142-3p down-regulation contributes to thyroid follicular tumorigenesis by targeting ASH1L and MLL1[J].J Clin Endocrinol Metab,2015,100(1):E59-E69.DOI:10.1210/jc.2014-2280.
[15] Mancikova V,Castelblanco E, Pineiro-Yanez E,et al. MicroRNA deep-sequencing reveals master regulators of follicular and papillary thyroid tumors[J].Mod Pathol,2015,28(6):748-757.DOI:10.1038/modpathol.2015.44.
[16] Colamaio M,Calì G, Sarnataro D,et al. Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXYD5(Dysadherin)gene[J].J Clin Endocrinol Metab, 2012,97(11): E2168-E2178.DOI:10.1210/jc.2012-1929.
[17] 耿艳,徐书杭,鲁一兵,等. 非编码RNA在分化型甲状腺癌分子诊断中的作用[J].国际内分泌代谢杂志,2017,37(2):101-104. DOI:10.3760/cma.j.issn.1673-4157.2017.02.008.
[18] Accardo G,Conzo G,Esposito D,et al. Genetics of medullary thyroid cancer: an overview[J]. Int J Surg,2017,41(Suppl 1):S2-S6.DOI:10.1016/j.ijsu.2017.02.064.
[19] Abraham D,Jackson N,Gundara JS,et al. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets[J].Clin Cancer Res,2011,17(14):4772-4781. DOI:10.1158/1078-0432.CCR-11-0242.
[20] Mian C,Pennelli G,Fassan M,et al. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome[J].Thyroid,2012,22(9):890-896.DOI:10.1089/thy.2012.0045.
[21] Pennelli G,Galuppini F,Barollo S,et al. The PDCD4/miR-21 pathway in medullary thyroid carcinoma[J].Hum Pathol,2015,46(1):50-57.DOI:10.1016/j.humpath.2014.09.006.
[22] Molinaro E, Romei C, Biagini A,et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies[J].Nat Rev Endocrinol,2017,13(11):644-660.DOI:10.1038/nrendo.2017.76.
[23] Esposito F,Tornincasa M,Pallante P,et al.Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2[J].J Clin Endocrinol Metab,2012,97(5):E710-E718.DOI:10.1210/jc.2011-3068.
[24] Huang HG,Luo X,Wu S,et al. MiR-99a inhibits cell proliferation and tumorigenesis through targeting mTOR in human anaplastic thyroid cancer[J].Asian Pac J Cancer Prev,2015,16(12):4937-4944.
[25] Braun J,Hoang-Vu C,Dralle H,et al. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas[J].Oncogene,2010,29(29):4237-4244. DOI:10.1038/onc.2010.169.
[26] Boufraqech M,Nilubol N,Zhang L,et al. miR30a inhibits LOX expression and anaplastic thyroid cancer progression[J]. Cancer Res,2015,75(2):367-377. DOI:10.1158/0008-5472.CAN-14-2304.
[27] Bu Q,You F,Pan G,et al. MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD[J].Biomed Pharmacother,2017,88:443-448.DOI:10.1016/j.biopha.2016.11.090.
[28] Pishkari S,Paryan M,Hashemi M,et al. The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies[J].J Endocrinol Invest,2017.DOI:10.1007/s40618-017-0735-6.
相似文献/References:
[1]于亚静 杨彩哲 关小宏 王良宸 吴石白 刘明 肖黎 张妲 刘朝阳.甲状腺癌与桥本甲状腺炎及其他相关危险因素的研究[J].国际内分泌代谢杂志,2015,(01):27.[doi:10.3760/cma.j.issn.1673-4157.2015.01.006]
Yu Yajing*,Yang Caizhe,Guan Xiaohong,et al.Relationship between thyroid carcinoma, Hashimoto′s thyroiditis and other related risk factors[J].International Journal of Endocrinology and Metabolism,2015,(03):27.[doi:10.3760/cma.j.issn.1673-4157.2015.01.006]
[2]李兴佳 曹萌 刘超.自噬与甲状腺癌的关系[J].国际内分泌代谢杂志,2015,(01):56.[doi:10.3760/cma.j.issn.1673-4157.2015.01.014]
Li Xingjia,Cao Meng,Liu Chao..Relationship between autophagy and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2015,(03):56.[doi:10.3760/cma.j.issn.1673-4157.2015.01.014]
[3]杨成会,缪珩.二甲双胍在甲状腺疾病治疗中的作用[J].国际内分泌代谢杂志,2015,(04):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
Yang Chenghui,Miao Heng..Roles of metformin in the treatment of thyroid diseases[J].International Journal of Endocrinology and Metabolism,2015,(03):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
[4]孟祥慧,徐书杭,蔡可英,等.肥胖与甲状腺癌：临床新启示[J].国际内分泌代谢杂志,2014,(02):87.[doi:10.3760/cma.j.issn.1673-4157.2014.02.005]
Meng Xianghui*,Xu Shuhang,Cai Keying,et al.Obesity and thyroid cancer: a new clinical implication[J].International Journal of Endocrinology and Metabolism,2014,(03):87.[doi:10.3760/cma.j.issn.1673-4157.2014.02.005]
[5]孙洪平,陈国芳,曹雯,等.糖尿病与甲状腺癌关系的研究进展[J].国际内分泌代谢杂志,2014,(02):90.[doi:10.3760/cma.j.issn.1673-4157.2014.02.006]
Sun Hongping,Chen Guofang,Cao Wen,et al.Diabetes and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2014,(03):90.[doi:10.3760/cma.j.issn.1673-4157.2014.02.006]
[6]于亚静,杨彩哲,关小宏,等.桥本甲状腺炎和甲状腺癌的关系[J].国际内分泌代谢杂志,2014,(03):200.[doi:10.3760/cma.j.issn.1673-4157.2014.03.016]
Yu Yajing,Yang Caizhe,Guan Xiaohong,et al.Relationship between Hashimoto's thyroiditis and thyroid carcinoma[J].International Journal of Endocrinology and Metabolism,2014,(03):200.[doi:10.3760/cma.j.issn.1673-4157.2014.03.016]
[7]任秀利 柳艳萍 宋富军 王亭 倪明 张平平 刘明法.1990—2015年天津市滨海新区甲状腺癌
流行特征及长期发病趋势分析[J].国际内分泌代谢杂志,2020,40(02):73.[doi:10.3760/cma.j.issn.1673-4157.2020.02.001]
Ren Xiuli,Liu Yanping,Song Fujun,et al.Epidemiological characteristics and long-term trends of thyroid cancer in Binhai New Area of Tianjin from 1990 to 2015[J].International Journal of Endocrinology and Metabolism,2020,40(03):73.[doi:10.3760/cma.j.issn.1673-4157.2020.02.001]
[8]韦茂英,晏蔚田,魏璠,等.非编码RNA在糖尿病认知障碍中的作用[J].国际内分泌代谢杂志,2020,40(06):420.[doi:10.3760/cma.j.cn121383-20200322-03060]
Wei Maoying,Yan Weitian,Wei Fan,et al.Effects of non-coding RNA in diabetic cognitive impairment[J].International Journal of Endocrinology and Metabolism,2020,40(03):420.[doi:10.3760/cma.j.cn121383-20200322-03060]
[9]井超,王旭东.免疫治疗在甲状腺癌中的研究进展[J].国际内分泌代谢杂志,2021,41(05):459.[doi:10.3760/cma.j.cn121383-20210624-06069]
Jing Chao,Wang Xudong..Research progress of immunotherapy in thyroid cancer[J].International Journal of Endocrinology and Metabolism,2021,41(03):459.[doi:10.3760/cma.j.cn121383-20210624-06069]
[10]何茹,徐加杰.甲状腺癌免疫微环境的研究进展[J].国际内分泌代谢杂志,2023,43(01):30.[doi:10.3760/cma.j.cn121383-20211116-11047]
He Ru,Xu Jiajie..Advances in the study of immune microenvironment of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2023,43(03):30.[doi:10.3760/cma.j.cn121383-20211116-11047]